http://www.w3.org/ns/prov#value | - e regulatory authorizations may be achieved later than anticipated or not at all; that Mayne's sales force may not be as effective as anticipated and the collaboration with Mayne may not achieve the results expected; that IVAX has in the past and may in the future experience difficulties in obtaining raw materials and other components necessary for the production of paclitaxel, on commercially rea
|